Amryt Pharma, which is focused on treatments for orphan diseases, announces the appointment of Markus Ziener as Non-Executive Director.
Markus is currently Chief Financial Officer of Software AG Stiftung, which he joined in 2013 as a Director of Asset Management. Prior to joining Software AG Stiftung, a 20.9% shareholder in Amryt, he worked in a number of senior roles across a broad range of industries.
Harry Stratford, Chairman of Amryt, said: "I am delighted to welcome Markus to the Board of Amryt. As the Director of Asset Management within Software AG Stiftung, Markus has been a long term supporter of the Birken business and was Chairman of the Supervisory Board until the Company's recent acquisition by Amryt. In this role, Markus was ultimately responsible for funding the development of our lead product, Episalvan, which has recently been approved in January by the European regulatory authorities for the treatment of partial thickness wounds. Together with our existing Imlan product range and the opportunity to also develop Episalvan in the rare disease Epidermolysis Bullosa, we are particularly excited about the future potential for the Amryt business."